• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Biomol Struct Dyn . Virtual screening of approved clinic drugs with main protease (3CL pro) reveals potential inhibitory effects on SARS-CoV-2

tetano

Editor, Senior Moderator
J Biomol Struct Dyn


. 2020 Sep 10;1-11.
doi: 10.1080/07391102.2020.1817786. Online ahead of print.
Virtual screening of approved clinic drugs with main protease (3CL [SUP]pro[/SUP]) reveals potential inhibitory effects on SARS-CoV-2


Qiang Wang[SUP] 1 2 3 4 5 [/SUP], Ying Zhao[SUP] 1 2 3 4 5 [/SUP], Xiaojia Chen[SUP] 1 2 3 4 5 [/SUP], An Hong[SUP] 1 2 3 4 5 [/SUP]



Affiliations

Abstract

3CL[SUP]pro[/SUP] is the main protease of the novel coronavirus (SARS-CoV-2) responsible for their intracellular duplication. Based on virtual screening technology and molecular dynamics simulation, we found 23 approved clinical drugs such as Viomycin, Capastat, Carfilzomib and Saquinavir, which showed high affinity with the 3CL[SUP]pro[/SUP] active sites. These findings showed that there were potential drugs that inhibit SARS-Cov-2's 3CL[SUP]pro[/SUP] in the current clinical drug library, and these drugs can be further tested or chemically modified for the treatment of COVID-19. Communicated by Ramaswamy H. Sarma.

Keywords: 3CLpro; SARS-CoV-2; approved drugs; molecular dynamics; virtual screening
 
Back
Top Bottom